Sensei Biotherapeutics (NASDAQ:FTH) Earns Outperform Rating from Analysts at Oppenheimer

Oppenheimer began coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research note published on Tuesday morning, MarketBeat reports. The firm issued an outperform rating and a $60.00 target price on the stock.

A number of other research analysts have also recently issued reports on the stock. Citizens Jmp began coverage on shares of Sensei Biotherapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective for the company. Leerink Partners assumed coverage on shares of Sensei Biotherapeutics in a report on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price on the stock. Loop Capital set a $50.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. Citigroup began coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They set a “buy” rating and a $55.00 price target for the company. Finally, HC Wainwright assumed coverage on Sensei Biotherapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $60.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $54.75.

Sensei Biotherapeutics Trading Down 0.4%

Shares of FTH opened at $28.82 on Tuesday. Sensei Biotherapeutics has a 12-month low of $7.10 and a 12-month high of $37.90. The firm has a market capitalization of $38.62 million, a P/E ratio of -0.20 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. As a group, sell-side analysts forecast that Sensei Biotherapeutics will post -16.61 earnings per share for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In other news, CFO Brian C. Stephenson bought 5,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was bought at an average price of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the acquisition, the chief financial officer directly owned 46,688 shares in the company, valued at approximately $1,097,168. This trade represents a 11.99% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Anand Kiran Parikh bought 2,806 shares of the stock in a transaction dated Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, with a total value of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. The trade was a 0.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 49,494 shares of company stock worth $1,188,822 in the last quarter. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after buying an additional 1,100 shares in the last quarter. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter worth approximately $4,188,000. Bank of America Corp DE grew its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Finally, Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.